Reports
Sale
Global Multiplexed Diagnostics Market Size, Share, Trends: By Product Type: Instruments and Accessories, Consumables; By Technology: High Density Multiplexed Assay, Medium Density Multiplexed Assay, Low Density Multiplexed Assay; By Application; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Global Multiplexed Diagnostics Market Outlook
The global multiplexed diagnostics market size was valued at USD 12.9 billion in 2023, driven by the growing demand for advanced diagnostic technology. The market is expected to grow at a CAGR of 15.2% during the forecast period of 2024-2032, with the values likely to rise from USD 14.9 billion in 2024 to USD 46.2 billion by 2032.
Global Multiplexed Diagnostics Market Overview
Multiplexing is the process of identifying or detecting multiple biomarkers at the same time in a single diagnostic test. Multiplexed diagnostics are highly valuable in certain disease types such as cardiovascular and infectious diseases to detect relevant biomarkers and guide the most optimal treatment plan. The clinically available multiplex diagnostics typically offer services to detect peptide or protein biomarkers and nucleic acid testing.
The rise in the prevalence of chronic disease directly impacts the multiplexed diagnostics market demand positively. Recent data suggests that chronic diseases are responsible for the mortality of 41 million people annually, which accounts for 74% of all deaths globally. Cardiovascular diseases account for most of the deaths in the chronic diseases category, reported to be 17.9 million in a year. To tackle the rising burden of chronic diseases and associated mortality, there is an increased emphasis on the development of multiplexed diagnostics to get actionable health insights in less time and cost.
The surge in approvals of multiplexed diagnostic platforms by health regulatory agencies such as the United States Food and Drug Administration (FDA) is expected to bolster the market growth. In March 2024, DiaSorin SpA received 510(k) clearance from the FDA for its new fully automated multiplexing platform LIAISON PLEX platform and its first panel of tests, LIAISON PLEX Respiratory Flex Assay. Through its innovative and cost-efficient multiplex molecular diagnostic platform, the company will gain access to the lucrative syndromic multiplexing market. The availability of such multiplexing platforms that maximize testing efficiencies in the laboratories is anticipated to boost the multiplexed diagnostics market share in the forecast period.
Other factors that are driving the market growth are the increased investment in genomic research from various sectors, rising healthcare expenditure, and the growing demand for personalized medicine. Moreover, the rising collaborations among the key market players are likely to accelerate the development of more sophisticated and advanced multiplexed diagnostic platforms.
Global Multiplexed Diagnostics Market Trends
| Key Trend | Impact |
| Technological Advancements | Technological advancements in multiplexing technologies have led to increased efficiency and throughput of diagnostic tests. Innovations such as microarray platforms and next-generation sequencing are driving the market demand as they allow simultaneous analysis of multiple biomarkers, reducing the time and cost per analysis. Thus, technological advancement in multiplexed diagnostic techniques is fostering their rapid adoption in clinical laboratories. |
| Increased Demand for Point-of-Care Testing | The market is witnessing growing demand for point-of-care (POC) testing which is driving the development of compact and user-friendly multiplexed diagnostic devices suitable for use outside traditional laboratory settings. Multiplexed POC devices are increasingly employed for getting timely and actionable health information and are expected to boost the multiplexed diagnostics market size in the coming years. This trend is particularly helpful in remote areas, where access to diagnostic facilities can prove challenging. |
| Integration of AI and Data Analytics | The integration of artificial intelligence (AI) and data analytics into multiplexed diagnostics is enhancing data interpretation and enabling predictive insights. This integration improves diagnostic accuracy along with allowing the identification of complex patterns in large datasets. In addition, the impact also includes the advancement of precision medicine, with customized treatments and prognostic assessments becoming more refined and accurate. |
| Emphasis on Personalized Medicine | The multiplexed diagnostics market value is likely to increase owing to the growing interest in personalized medicine and tailored treatment plans based on individual patient profiles. Simultaneous analysis of various genetic, proteomic, and metabolic markers through such diagnostics helps in the identification of patient-specific disease characteristics and treatment responses. Moreover, this trend fuels the development of targeted therapies and contributes to the optimization of treatment strategies. |
Global Multiplexed Diagnostics Market Segmentation
Market Breakup by Product Type
- Instruments and Accessories
- Consumables
The market segmentation by product type comprises instruments and accessories, along with consumables. Consumables include reagents and assay kits required during multiplexed diagnostics procedures.
Market Breakup by Technology
- High Density Multiplexed Assay
- Medium Density Multiplexed Assay
- Low Density Multiplexed Assay
On the basis of technology, multiplexed diagnostics can be categorized as high-density multiplexed assays, medium density multiplexed assays, and low density multiplexed assays. This market segment reflects the varying levels of multiplexing capabilities offered by different platforms.
Market Breakup by Application
- Infectious Disease
- Autoimmune Disease
- Cardiac Disease
- Oncology
- Others
Multiplexed diagnostics market demand has elevated in recent times, owing to its increased application in various domains. It is used across infectious diseases, autoimmune diseases, cardiac diseases, oncology, and other medical conditions. This segment provides a wide range of diagnostic needs across different specialties.
Market Breakup by End User
- Hospitals
- Diagnostic Centers
- Others
End-users of multiplexed diagnostics include hospitals, diagnostic centers, and other healthcare facilities where patients undergo diagnostic testing.
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Geographically, the multiplexed diagnostics market report offers insights for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The regional disparity in the market growth relies on factors such as advancement in the healthcare infrastructure, the prevalence and incidence of diseases, and the adoption rate of multiplexed diagnostic technologies. North America leads the market segment, which can be attributed to the significant healthcare expenditure and the availability of advanced technologies in the healthcare facilities. Moreover, the increased investment by public and private sectors in the life science research is also expected to drive the market growth in the coming years.
Global Multiplexed Diagnostics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- DiaSorin S.p.A
- Thermo Fisher Scientific Corporation
- QIAGEN N.V.
- Siemens Healthineers
- BioMerieux
- Agilent Technologies Inc.
- F. Hoffmann La Roche Ltd.
- Illumina Inc.
- Hologic Inc.
- Co-Diagnostics, Inc.
- Abbott Laboratories
- Bio-Rad Laboratories Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Technology |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Global Multiplexed Diagnostics Market Report
- How is the market landscape expected to evolve in upcoming years?
- What are the major market trends influencing the market?
- What are the major drivers, opportunities, and restraints in the market?
- What will be the effect of each driver, challenge, and opportunity on the market?
- Which region is poised to lead the market share in the forecast period?
- Which regional market is expected to experience expedited growth during the forecast period?
- Which product type will experience the highest demand in the market?
- Which technology type is expected to dominate the respective market segment?
- Which applications are expected to significantly impact the multiplexed diagnostics market growth?
- What are the key research initiatives expected to boost the market value during the forecast period?
- What are the regulatory frameworks impacting the market growth?
- How is technological advancement shaping the future of the market?
- How is the integration of automation and artificial intelligence influencing the market size?
- How are partnerships, collaborations, and mergers and acquisitions shaping the market dynamics of the electrophoresis equipment industry?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Multiplexed Diagnostics Market Overview
3.1 Global Multiplexed Diagnostics Market Historical Value (2017-2023)
3.2 Global Multiplexed Diagnostics Market Forecast Value (2024-2032)
4 Global Multiplexed Diagnostics Market Landscape*
4.1 Global Multiplexed Diagnostics: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Multiplexed Diagnostics: Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Technology
4.2.3 Analysis by Application
5 Global Multiplexed Diagnostics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Multiplexed Diagnostics Market Segmentation (2017-2032)
6.1 Global Multiplexed Diagnostics Market (2017-2032) by Product Type
6.1.1 Market Overview
6.1.2 Instruments and Accessories
6.1.3 Consumables
6.2 Global Multiplexed Diagnostics Market (2017-2032) by Technology
6.2.1 Market Overview
6.2.2 High Density Multiplexed Assay
6.2.3 Medium Density Multiplexed Assay
6.2.4 Low Density Multiplexed Assay
6.3 Global Multiplexed Diagnostics Market (2017-2032) by Application
6.3.1 Market Overview
6.3.2 Infectious Disease
6.3.3 Autoimmune Disease
6.3.4 Cardiac Disease
6.3.5 Oncology
6.3.6 Others
6.4 Global Multiplexed Diagnostics Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Diagnostic Centers
6.4.4 Others
6.5 Global Multiplexed Diagnostics Market (2017-2032) by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Multiplexed Diagnostics Market (2017-2032)
7.1 North America Multiplexed Diagnostics Market (2017-2032) by Product Type
7.1.1 Market Overview
7.1.2 Instruments and Accessories
7.1.3 Consumables
7.2 North America Multiplexed Diagnostics Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Infectious Disease
7.2.3 Autoimmune Disease
7.2.4 Cardiac Disease
7.2.5 Oncology
7.2.6 Others
7.3 North America Multiplexed Diagnostics Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Multiplexed Diagnostics Market (2017-2032)
8.1 Europe Multiplexed Diagnostics Market (2017-2032) by Product Type
8.1.1 Market Overview
8.1.2 Instruments and Accessories
8.1.3 Consumables
8.2 Europe Multiplexed Diagnostics Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Infectious Disease
8.2.3 Autoimmune Disease
8.2.4 Cardiac Disease
8.2.5 Oncology
8.2.6 Others
8.3 Europe Multiplexed Diagnostics Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Multiplexed Diagnostics Market (2017-2032)
9.1 Asia Pacific Multiplexed Diagnostics Market (2017-2032) by Product Type
9.1.1 Market Overview
9.1.2 Instruments and Accessories
9.1.3 Consumables
9.2 Asia Pacific Multiplexed Diagnostics Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Infectious Disease
9.2.3 Autoimmune Disease
9.2.4 Cardiac Disease
9.2.5 Oncology
9.2.6 Others
9.3 Asia Pacific Multiplexed Diagnostics Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Multiplexed Diagnostics Market (2017-2032)
10.1 Latin America Multiplexed Diagnostics Market (2017-2032) by Product Type
10.1.1 Market Overview
10.1.2 Instruments and Accessories
10.1.3 Consumables
10.2 Latin America Multiplexed Diagnostics Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Infectious Disease
10.2.3 Autoimmune Disease
10.2.4 Cardiac Disease
10.2.5 Oncology
10.2.6 Others
10.3 Latin America Multiplexed Diagnostics Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Multiplexed Diagnostics Market (2017-2032)
11.1 Middle East and Africa Multiplexed Diagnostics Market (2017-2032) by Product Type
11.1.1 Market Overview
11.1.2 Instruments and Accessories
11.1.3 Consumables
11.2 Middle East and Africa Multiplexed Diagnostics Market (2017-2032) by Application
11.2.1 Market Overview
11.2.2 Infectious Disease
11.2.3 Autoimmune Disease
11.2.4 Cardiac Disease
11.2.5 Oncology
11.2.6 Others
11.3 Middle East and Africa Multiplexed Diagnostics Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 DiaSorin S.p.A
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Thermo Fisher Scientific Corporation
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 QIAGEN N.V.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Siemens Healthineers
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 BioMerieux
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Agilent Technologies Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 F. Hoffmann La Roche Ltd.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Illumina Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Hologic Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Co-Diagnostics, Inc.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Abbott Laboratories
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Bio-Rad Laboratories Inc.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
18 Global Multiplexed Diagnostics Market – Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 12.9 billion in 2023 driven by the growing demand for advanced diagnostic technology across the globe.
The market is anticipated to grow at a CAGR of 15.2% during the forecast period of 2024-2032, likely to reach a market value of USD 46.2 billion by 2032.
Technological advancements in the multiplexed diagnostic platform and the increased healthcare expenditure are fuelling the demand for the market.
One of the significant trends in the market is the surge in approvals of multiplexed diagnostic platforms by health regulatory agencies such as the United States Food and Drug Administration (FDA). In March 2024, DiaSorin SpA received FDA 510(k) clearance for its new fully automated multiplexing platform LIAISON PLEX platform and its first panel of tests, LIAISON PLEX Respiratory Flex Assay.
Based on the product, the market comprises instruments and accessories, along with consumables.
On the basis of technology, multiplexed diagnostics can be categorized as high-density multiplexed assays, medium density multiplexed assays, and low density multiplexed assays.
Major end users of multiplexed diagnostics include hospitals, diagnostic centers, and other healthcare facilities
Applications of multiplexed diagnostics can be found across infectious diseases, autoimmune diseases, cardiac diseases, oncology, and other medical conditions.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
Key players involved in the market are DiaSorin S.p.A, Thermo Fisher Scientific Corporation, QIAGEN N.V., Siemens Healthineers, BioMerieux, Agilent Technologies Inc., F. Hoffmann La Roche Ltd., Illumina Inc., Hologic Inc., Co-Diagnostics, Inc., Abbott Laboratories, and Bio-Rad Laboratories Inc.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER